CY1111571T1 - INHALATED AZRONEONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS - Google Patents
INHALATED AZRONEONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONSInfo
- Publication number
- CY1111571T1 CY1111571T1 CY20111100581T CY111100581T CY1111571T1 CY 1111571 T1 CY1111571 T1 CY 1111571T1 CY 20111100581 T CY20111100581 T CY 20111100581T CY 111100581 T CY111100581 T CY 111100581T CY 1111571 T1 CY1111571 T1 CY 1111571T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- bacterial infections
- azroneonam
- inhalated
- prevention
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 2
- 230000002685 pulmonary effect Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 241001673062 Achromobacter xylosoxidans Species 0.000 abstract 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 241000589513 Burkholderia cepacia Species 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 241000606768 Haemophilus influenzae Species 0.000 abstract 1
- 241000588749 Klebsiella oxytoca Species 0.000 abstract 1
- 241000588747 Klebsiella pneumoniae Species 0.000 abstract 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 abstract 1
- 229960003644 aztreonam Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940047650 haemophilus influenzae Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Μέθοδος και σύνθεση για τη θεραπεία πνευμονικών βακτηριακών λοιμώξεων που προκαλούνται από gram αρνητικά βακτήρια, κατάλληλη για τη θεραπεία λοιμώξεων που προκαλούνται από Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, είδη Enterobacter, Serratia marcescens καθώς και εκείνων που προκαλούνται από Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans και ανθεκτική σε πολλά φάρμακα Pseudomonas aeruginosa, με χρήση συμπυκνωμένης τυποποίησης αζτρεονάμης ή φαρμακευτικώς αποδεκτού άλατος της, η οποία χορηγείται ως τυποποίηση αερολύματος ή ξηράς σκόνης.Method and composition for the treatment of pulmonary bacterial infections caused by gram negative bacteria, suitable for the treatment of infections caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilote influenzae, caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans and many drug-resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam or its pharmaceutically acceptable salt, which is administered as an aerosol formulation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25842300P | 2000-12-27 | 2000-12-27 | |
EP01991523A EP1353647B1 (en) | 2000-12-27 | 2001-12-20 | Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111571T1 true CY1111571T1 (en) | 2014-04-09 |
Family
ID=22980480
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100581T CY1111571T1 (en) | 2000-12-27 | 2011-06-16 | INHALATED AZRONEONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS |
CY2011012C CY2011012I1 (en) | 2000-12-27 | 2011-08-22 | INHALED AZTREONAME FOR THE TREATMENT AND PREVENTION OF BACTERIAL PULMONARY INFECTIONS |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY2011012C CY2011012I1 (en) | 2000-12-27 | 2011-08-22 | INHALED AZTREONAME FOR THE TREATMENT AND PREVENTION OF BACTERIAL PULMONARY INFECTIONS |
Country Status (19)
Country | Link |
---|---|
US (6) | US6660249B2 (en) |
EP (2) | EP1353647B1 (en) |
JP (1) | JP4646489B2 (en) |
AT (1) | ATE502623T1 (en) |
AU (1) | AU2002231244B2 (en) |
BE (1) | BE2011C029I2 (en) |
BR (1) | BRPI0116757B8 (en) |
CA (2) | CA2708703C (en) |
CY (2) | CY1111571T1 (en) |
DE (2) | DE60144291D1 (en) |
DK (2) | DK1353647T3 (en) |
ES (2) | ES2360692T3 (en) |
FR (1) | FR11C0030I2 (en) |
IL (3) | IL156596A0 (en) |
LU (1) | LU91851I2 (en) |
NL (1) | NL300492I2 (en) |
NO (3) | NO329643B1 (en) |
PT (2) | PT2301524E (en) |
WO (1) | WO2002051356A2 (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7214364B2 (en) * | 2000-12-27 | 2007-05-08 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
ES2360692T3 (en) | 2000-12-27 | 2011-06-08 | Gilead Sciences, Inc. | INHALABLE AZTREONAM FOR TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS. |
US7138419B2 (en) * | 2000-12-27 | 2006-11-21 | Corus Pharma, Inc. | Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate |
US20030133925A1 (en) * | 2001-09-28 | 2003-07-17 | Shawar Ribhi M. | Monobactam compositions and methods of use thereof |
JP2005530704A (en) * | 2002-03-05 | 2005-10-13 | トランセイブ, インク. | Inhalation system for preventing and treating intracellular infections |
US7607436B2 (en) | 2002-05-06 | 2009-10-27 | The Research Foundation Of State University Of New York | Methods, devices and formulations for targeted endobronchial therapy |
JP2006514608A (en) | 2002-08-05 | 2006-05-11 | テバ ジョジセルジャール レースベニュタールシャシャーグ | Preparation of aztreonam |
WO2004052333A1 (en) * | 2002-12-11 | 2004-06-24 | Pari Gmbh | Pharmaceutical compositions for the pulmonary delivery of aztreonam |
JP2006522634A (en) | 2003-04-14 | 2006-10-05 | ベクトゥラ・リミテッド | Device and pharmaceutical composition for improving administration efficiency |
US20060147389A1 (en) * | 2004-04-14 | 2006-07-06 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
CN1802371A (en) | 2003-05-15 | 2006-07-12 | 特瓦药厂有限公司 | Aztreonam beta-polymorph with very low residual solvent content |
US7883031B2 (en) * | 2003-05-20 | 2011-02-08 | James F. Collins, Jr. | Ophthalmic drug delivery system |
AU2004256124B2 (en) * | 2003-07-02 | 2011-04-28 | Corus Pharma, Inc. | Aztreonam L-lysine and methods for the preparation thereof |
AU2014271333B2 (en) * | 2003-07-03 | 2016-10-27 | Gilead Sciences, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
AU2004257632C1 (en) * | 2003-07-03 | 2010-04-15 | Gilead Sciences, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
US7452523B2 (en) * | 2004-01-27 | 2008-11-18 | Gilead Sciences, Inc. | Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks |
US20050207983A1 (en) * | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
US20060210483A1 (en) * | 2005-03-02 | 2006-09-21 | Kodsi Robert E | Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections |
US7601832B2 (en) | 2005-05-09 | 2009-10-13 | Sicor, Inc. | Process for making aztreonam |
US20080107723A1 (en) * | 2006-09-28 | 2008-05-08 | Perkins Walter R | Methods of Treating Pulmonary Distress |
HUP0700007A2 (en) * | 2007-01-08 | 2008-10-28 | Asthma Rehabilitacios Ct Kft | Device and process for producing of natrium chloride aerosol for the disorders of the respiratory system |
CN101715349B (en) * | 2007-05-08 | 2012-07-18 | 美国Rq生物科技有限公司 | Therapeutic compositions and methods for treating gram-negative bacterial infections |
GB0714134D0 (en) * | 2007-07-19 | 2007-08-29 | Norton Healthcare Ltd | Dry-powder medicament |
CA2701118A1 (en) * | 2007-10-01 | 2009-04-09 | Gilead Sciences, Inc. | Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases |
DK2268142T3 (en) | 2007-11-27 | 2017-05-22 | Algipharma As | USING ALGINATED OLIGOMERS TO FIGHT BIOFILM |
EP2098219A1 (en) | 2008-03-05 | 2009-09-09 | PARI Pharma GmbH | Macrolide compositions having improved taste and stability |
US20090271021A1 (en) * | 2008-04-28 | 2009-10-29 | Popp Shane M | Execution system for the monitoring and execution of insulin manufacture |
JP5671001B2 (en) | 2009-03-26 | 2015-02-18 | パルマトリックス,インコーポレイテッド | Dry powder formulation and method for treating lung disease |
US9018158B2 (en) | 2009-06-03 | 2015-04-28 | Algipharma As | Alginate oligomers for use in overcoming multidrug resistance in bacteria |
US10154923B2 (en) | 2010-07-15 | 2018-12-18 | Eyenovia, Inc. | Drop generating device |
EP2611438B1 (en) | 2010-08-30 | 2020-04-01 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
US20120076859A1 (en) * | 2010-09-23 | 2012-03-29 | Activaero Gmbh | Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases |
MX354828B (en) | 2010-09-29 | 2018-03-22 | Pulmatrix Operating Co Inc | Monovalent metal cation dry powders for inhalation. |
DK3470057T3 (en) | 2010-09-29 | 2021-11-22 | Pulmatrix Operating Co Inc | CATIONIC DRY POWDER INCLUDING MAGNESIUM SALT |
WO2013109217A1 (en) * | 2012-01-16 | 2013-07-25 | Mahmut Bilgic | Pharmaceutical formulations comprising aztreonam |
CN107596518B (en) | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | Inhalable dry powder |
EP2978434A4 (en) * | 2013-03-28 | 2016-08-17 | Pharmacaribe Llc | Compositions, formulations and methods of bio-balancing the ph of sterile isotonic saline and hypertonic saline solutions |
WO2014165303A1 (en) | 2013-04-01 | 2014-10-09 | Pulmatrix, Inc. | Tiotropium dry powders |
CN104784159A (en) * | 2015-04-15 | 2015-07-22 | 苏州惠仁生物科技有限公司 | Method for preparing aztreonam powder aerosol |
JP6774508B2 (en) | 2016-05-03 | 2020-10-28 | ニューマ・リスパイラトリー・インコーポレイテッド | Drop model delivery device for supplying fluid to the lung system and how to use it |
CA3064005C (en) | 2017-05-19 | 2023-03-07 | Pneuma Respiratory, Inc. | Dry powder delivery device and methods of use |
JP7227163B2 (en) | 2017-06-10 | 2023-02-21 | アイノビア,インコーポレイティド | Methods and apparatus for handling and delivering fluids to the eye |
WO2019071008A1 (en) | 2017-10-04 | 2019-04-11 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device and methods of use |
EP4344719A2 (en) | 2017-10-17 | 2024-04-03 | Pneuma Respiratory, Inc. | Nasal drug delivery apparatus and methods of use |
JP2021502178A (en) | 2017-11-08 | 2021-01-28 | ニューマ・リスパイラトリー・インコーポレイテッド | In-line droplet delivery device with a small volume ampoule and electrically actuated by breathing and how to use |
CN110898040B (en) * | 2018-09-18 | 2022-05-17 | 北京盈科瑞创新药物研究有限公司 | Freeze-dried powder for aztreonam solution for inhalation and preparation method thereof |
CN111647537B (en) * | 2020-06-18 | 2022-04-26 | 浙江工业大学 | Salt-tolerant capsaicin degrading bacteria, application and kitchen waste treatment method |
EP4359046A1 (en) | 2021-06-22 | 2024-05-01 | Pneuma Respiratory, Inc. | Droplet delivery device with push ejection |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US572801A (en) * | 1896-12-08 | Telephone-exchange | ||
US9126A (en) * | 1852-07-13 | Marcus r | ||
US610824A (en) * | 1898-09-13 | Sleigh attachment for vehicles | ||
US673739A (en) * | 1900-09-19 | 1901-05-07 | Frank B Stearns | Driving mechanism for vehicles. |
US775670A (en) * | 1904-08-17 | 1904-11-22 | Thomas F Whittelsey | Air-brake safety device. |
US946838A (en) * | 1909-08-17 | 1910-01-18 | George Dawson | Tempering compound. |
US4775670A (en) | 1980-09-29 | 1988-10-04 | E. R. Squibb & Sons, Inc. | 2-oxo-1-azetidinesulfonic acid salts |
WO1982001873A1 (en) * | 1980-12-05 | 1982-06-10 | Takeda Chemical Industries Ltd | 1-sulfo-2-oxoazetidine derivatives and process for their preparation |
US4673739A (en) | 1980-12-05 | 1987-06-16 | Takeda Chemical Industries, Ltd. | 4-carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production |
US4529698A (en) * | 1981-01-19 | 1985-07-16 | E. R. Squibb & Sons, Inc. | Process for preparing a 2-oxo-1-azetidinesulfonic acid salt |
US4625022A (en) * | 1981-02-02 | 1986-11-25 | E. R. Squibb & Sons, Inc. | Process for preparing (s)-3-amino-2-oxo-1-azetidinesulfonic acid salts |
US4386034A (en) * | 1981-02-02 | 1983-05-31 | E. R. Squibb & Sons, Inc. | Sulfamated amino acid amides |
US4572801A (en) | 1981-04-30 | 1986-02-25 | Takeda Chemical Industries, Ltd. | 4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production |
US4946838A (en) | 1981-07-13 | 1990-08-07 | E. R. Squibb & Sons, Inc. | Crystalline anhydrous aztreonam |
CA1181075A (en) | 1981-07-13 | 1985-01-15 | David M. Floyd | CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID |
US4752469A (en) * | 1984-01-09 | 1988-06-21 | E. R. Squibb & Sons, Inc. | Potentiators of beta-lactam antibiotics |
US4826973A (en) * | 1984-07-20 | 1989-05-02 | E. R. Squibb & Sons, Inc. | Delta form of aztreonam and preparation thereof |
US4610824A (en) | 1984-10-09 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Hydrazide derivatives of monocyclic beta-lactam antibiotics |
US4888998A (en) * | 1986-07-11 | 1989-12-26 | Beckman Instruments, Inc. | Sample handling system |
CA1339136C (en) | 1987-07-01 | 1997-07-29 | Sailesh Amilal Varia | Amorphous form of aztreonam |
US5194604A (en) * | 1990-06-29 | 1993-03-16 | E. R. Squibb & Sons, Inc. | Process and intermediates for beta-lactams having aminothiazole(iminooxyacetic acid)acetic acid sidechains |
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
CA2105629A1 (en) * | 1992-09-14 | 1994-03-15 | Robert S. Becker | Potentiation of immunogenic response |
EP0754050B1 (en) * | 1994-01-14 | 2002-06-26 | XOMA Technology Ltd. | Anti gram positive bacterial methods and materials |
US5508269A (en) * | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
US5662929A (en) * | 1994-12-23 | 1997-09-02 | Universite De Montreal | Therapeutic liposomal formulation |
US5723495A (en) | 1995-11-16 | 1998-03-03 | The University Of North Carolina At Chapel Hill | Benzamidoxime prodrugs as antipneumocystic agents |
US5875776A (en) * | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
US6180604B1 (en) | 1996-08-21 | 2001-01-30 | Micrologix Biotech Inc. | Compositions and methods for treating infections using analogues of indolicidin |
KR100524245B1 (en) | 1996-09-04 | 2005-10-26 | 다카라 바이오 가부시키가이샤 | Fungal antigens and process for producing the same |
US5994340A (en) * | 1997-08-29 | 1999-11-30 | Synphar Laboratories, Inc. | Azetidinone derivatives as β-lactamase inhibitors |
CA2410694A1 (en) | 1998-06-16 | 1999-12-16 | Serge Dea | Porcine reproductive and respiratory syndrome virus (prrsv) dna vaccines |
CA2514899A1 (en) | 1998-08-31 | 2000-03-09 | Biogen, Inc. | Method of modulating memory effector t-cells and compositions |
JP2002532430A (en) * | 1998-12-17 | 2002-10-02 | パソゲネシス コーポレイション | Treatment of severe chronic bronchitis (bronchiectasis) using aerosolized antibiotics |
CA2375700A1 (en) | 1999-06-01 | 2000-12-07 | Biogen, Inc. | Polymer conjugates of hedgehog proteins and uses |
US6576224B1 (en) * | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
ATE313318T1 (en) * | 1999-10-29 | 2006-01-15 | Nektar Therapeutics | DRY POWDER COMPOSITIONS WITH IMPROVED DISPERSITY |
US6962151B1 (en) | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
DE19953317C1 (en) | 1999-11-05 | 2001-02-01 | Pari Gmbh | Aerosol generation unit for inhalation therapies, comprises a valve which allows patient's exhaled air to enter into the surroundings, but prevents direct entry of external air into the mixing chamber during the inhaling phase |
ES2360692T3 (en) | 2000-12-27 | 2011-06-08 | Gilead Sciences, Inc. | INHALABLE AZTREONAM FOR TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS. |
US7214364B2 (en) * | 2000-12-27 | 2007-05-08 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
US7138419B2 (en) * | 2000-12-27 | 2006-11-21 | Corus Pharma, Inc. | Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate |
WO2003031163A2 (en) * | 2001-10-08 | 2003-04-17 | California Institute Of Technology | Microfabricated lenses, methods of manufacture thereof, and applications therefor |
EP1438019A1 (en) | 2001-10-24 | 2004-07-21 | PARI GmbH Spezialisten für effektive Inhalation | Kit for the preparation of a pharmaceutical composition |
JP2005530704A (en) | 2002-03-05 | 2005-10-13 | トランセイブ, インク. | Inhalation system for preventing and treating intracellular infections |
EP1417958A1 (en) | 2002-11-08 | 2004-05-12 | Pari GmbH | Wet granulation process |
WO2004052333A1 (en) | 2002-12-11 | 2004-06-24 | Pari Gmbh | Pharmaceutical compositions for the pulmonary delivery of aztreonam |
AU2004256124B2 (en) | 2003-07-02 | 2011-04-28 | Corus Pharma, Inc. | Aztreonam L-lysine and methods for the preparation thereof |
CA2701118A1 (en) | 2007-10-01 | 2009-04-09 | Gilead Sciences, Inc. | Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases |
-
2001
- 2001-12-20 ES ES01991523T patent/ES2360692T3/en not_active Expired - Lifetime
- 2001-12-20 CA CA2708703A patent/CA2708703C/en not_active Expired - Lifetime
- 2001-12-20 CA CA2433280A patent/CA2433280C/en not_active Expired - Lifetime
- 2001-12-20 ES ES10010411T patent/ES2406405T3/en not_active Expired - Lifetime
- 2001-12-20 EP EP01991523A patent/EP1353647B1/en not_active Expired - Lifetime
- 2001-12-20 EP EP10010411.6A patent/EP2301524B1/en not_active Revoked
- 2001-12-20 DE DE60144291T patent/DE60144291D1/en not_active Expired - Lifetime
- 2001-12-20 US US10/027,113 patent/US6660249B2/en not_active Expired - Lifetime
- 2001-12-20 WO PCT/US2001/050062 patent/WO2002051356A2/en active Application Filing
- 2001-12-20 AT AT01991523T patent/ATE502623T1/en active
- 2001-12-20 BR BRPI0116757A patent/BRPI0116757B8/en not_active IP Right Cessation
- 2001-12-20 JP JP2002552504A patent/JP4646489B2/en not_active Expired - Lifetime
- 2001-12-20 DE DE201112100043 patent/DE122011100043I1/en active Pending
- 2001-12-20 IL IL15659601A patent/IL156596A0/en unknown
- 2001-12-20 PT PT100104116T patent/PT2301524E/en unknown
- 2001-12-20 AU AU2002231244A patent/AU2002231244B2/en active Active
- 2001-12-20 DK DK01991523.0T patent/DK1353647T3/en active
- 2001-12-20 DK DK10010411.6T patent/DK2301524T3/en active
- 2001-12-20 PT PT01991523T patent/PT1353647E/en unknown
-
2003
- 2003-06-23 IL IL156596A patent/IL156596A/en active Protection Beyond IP Right Term
- 2003-06-26 NO NO20032946A patent/NO329643B1/en not_active IP Right Cessation
- 2003-09-04 US US10/654,815 patent/US7208141B2/en not_active Expired - Lifetime
-
2007
- 2007-03-28 US US11/729,698 patent/US20080050439A1/en not_active Abandoned
-
2010
- 2010-10-05 NO NO20101377A patent/NO20101377L/en not_active Application Discontinuation
-
2011
- 2011-01-25 NO NO2011001C patent/NO2011001I2/en unknown
- 2011-06-16 CY CY20111100581T patent/CY1111571T1/en unknown
- 2011-08-03 LU LU91851C patent/LU91851I2/en unknown
- 2011-08-05 NL NL300492C patent/NL300492I2/en unknown
- 2011-08-16 FR FR11C0030C patent/FR11C0030I2/en active Active
- 2011-08-22 CY CY2011012C patent/CY2011012I1/en unknown
- 2011-09-08 BE BE2011C029C patent/BE2011C029I2/fr unknown
- 2011-12-19 US US13/330,633 patent/US20120093890A1/en not_active Abandoned
-
2012
- 2012-07-19 IL IL221036A patent/IL221036A0/en unknown
-
2013
- 2013-10-04 US US14/046,539 patent/US9533000B2/en not_active Expired - Lifetime
-
2016
- 2016-11-15 US US15/352,364 patent/US20170296517A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111571T1 (en) | INHALATED AZRONEONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS | |
CY1114621T1 (en) | INSPECTION OF INHIBITED LYSINIC AZRTEONAMINE FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS | |
WO2011005354A3 (en) | Gallium formulation for the treatment and prevention of infectious diseases | |
NO20024772D0 (en) | Percyquinnin, process for its preparation and its use as a drug | |
WO2008105515A1 (en) | Novel hydroxamic acid derivative | |
ATE556061T1 (en) | THERAPEUTIC OR PROPHYLACTIC AGENT AGAINST MULTIPLE SCLEROSIS | |
WO2006116148A3 (en) | (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse | |
WO2004032909A3 (en) | Stabilized pharmaceutical composition containing basic excipients | |
WO2003097575A3 (en) | Amino-functional chalcones | |
DK1383752T3 (en) | Deuterated 3-piperidinopropiophenones as well as drugs containing these compounds | |
ES2133722T3 (en) | USE OF SIMPLE OR CONJUGATED DEXTRANS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO PREVENT OR REDUCE THE RISK OF INFECTION OF BACTERIAL PATHOGENIC GERMS. | |
BRPI0411623A (en) | pharmaceutical or dietary dosage form, sporopolenin, method for forming a primary amine-functionalized sporopolenin or other exine coating, method for forming a polyamino-functionalized sporopolenin or other spore exine coating, method for obtaining an amino acid functionalized sporopolenin or other spore exine coating, functionalized sporopolenin or other spore exine coating, dietary or flavoring dosage form, method of filling spore exine coatings, use of the dosage and method of oral application of an active ingredient | |
CY1114144T1 (en) | INHALATED AZRONEONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS | |
WO2002060533A3 (en) | Pharmaceutical compositions containing beta-mimetic agents and having few side-effects | |
PT1362590E (en) | USE OF CILOBRADINE OR OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE TREATMENT OR PREVENTION OF HEART FAILURE | |
UY26814A1 (en) | METHOD AND COMPOSITION | |
AR040420A1 (en) | INHALABLE AZTREONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS | |
TNSN06114A1 (en) | PHARMACEUTICAL FORMULATIONS, METHODS AND ADMINISTRATION DIAGRAMS FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES | |
AU2002360218A1 (en) | A METHOD OF TREATING BACTERIAL INFECTIONS USING GEMIFLOXACIN OR A SALT THEREOF AND A Beta -LACTAM ANTIBIOTIC | |
BR0307468A (en) | Antimicrobial Thiadiazinone Derivatives Useful in the Treatment of Bacterial Infections | |
WO2004056306A3 (en) | Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases | |
NO20035102D0 (en) | Use of a gatran for the manufacture of a medicament for the treatment of lung fibrosis | |
AR054219A1 (en) | FORMULATION OF INHALABLE AZTREONAM LISINATE FOR THE TREATMENT AND PREVENTION OF BACTERIAL PULMONARY INFECTIONS | |
BR0100379A (en) | Therapeutic use of the synthetic peptide klklllllklk-nh2 |